A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy

Abroad (travel likely)RecruitingPHASE2

Conditions

Large B-cell Lymphoma · Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

MD Anderson Cancer Center, Houston, Texas, United States
Contact: Study coordinator (Paolo Strati, MD) · pstrati@mdanderson.org · 713-745-1776
Contact: Principal Investigator (Paolo Strati, MD)

Study leads

Paolo Strati, MD
Principal Investigator
M.D. Anderson Cancer Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T

Large B-cell Lymphoma

Abroad (travel likely)RecruitingPHASE2

Toronto, Canada

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma · Recurrent Grade 3b Follicular Lymphoma · Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

Abroad (travel likely)RecruitingPHASE1, PHASE2

Minneapolis, United States · Columbus, United States

Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes

Diffuse Large B-Cell Lymphoma (DLBCL)

Abroad (travel likely)RecruitingPHASE2

Nanjing, China

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

B-cell Lymphoma · Burkitt Lymphoma · Diffuse Large B Cell Lymphoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Valhalla, United States